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Abstract
We analyzed the lung mRNA expression profiles of a murine model of COPD developed using a lung-specific IL-18-
transgenic mouse. In this transgenic mouse, the expression of 608 genes was found to vary more than 2-fold in comparison
with control WT mice, and was clustered into 4 groups. The expression of 140 genes was constitutively increased at all ages,
215 genes increased gradually with aging, 171 genes decreased gradually with aging, and 82 genes decreased temporarily
at 9 weeks of age. Interestingly, the levels of mRNA for the chitinase-related genes chitinase 3-like 1 (Chi3l1), Chi3l3, and
acidic mammalian chitinase (AMCase) were significantly higher in the lungs of transgenic mice than in control mice. The
level of Chi3l1 protein increased significantly with aging in the lungs and sera of IL-18 transgenic, but not WT mice. Previous
studies have suggested Chi3l3 and AMCase are IL-13-driven chitinase-like proteins. However, IL-13 gene deletion did not
reduce the level of Chi3l1 protein in the lungs of IL-18 transgenic mice. Based on our murine model gene expression data,
we analyzed the protein level of YKL-40, the human homolog of Chi3l1, in sera of smokers and COPD patients. Sixteen COPD
patients had undergone high resolution computed tomography (HRCT) examination. Emphysema was assessed by using a
density mask with a cutoff of 2950 Hounsfield units to calculate the low-attenuation area percentage (LAA%). We observed
significantly higher serum levels in samples from 28 smokers and 45 COPD patients compared to 30 non-smokers. In COPD
patients, there was a significant negative correlation between serum level of YKL-40 and %FEV1. Moreover, there was a
significant positive correlation between the serum levels of YKL-40 and LAA% in COPD patients. Thus our results suggest
that chitinase-related genes may play an important role in establishing pulmonary inflammation and emphysematous
changes in smokers and COPD patients.
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Introduction
Chronic obstructive pulmonary disease (COPD) is an important
pulmonary inflammatory disease whose prevalence and associated
mortality rates have been increasing [1,2]. In this disease, T cells
(predominantly IFN-c-producing CD8
+ T cells (type 1 cytotoxic T
cells) and Th1 cells), neutrophils and macrophages are activated in
the lungs [3,4], producing proteases such as neutrophil elastase
and matrix metalloproteinase (MMP)-9, resulting in alveolar wall
destruction (emphysematous change) and mucus hypersecretion.
COPD patients also show increased concentrations of MMP-1
(collagenase) and MMP-9 (gelatinase B) in bronchial lavage fluid
(BALF), and higher expression of these enzymes in lung macro-
phages [5]. In addition, various cytokines (e.g. IL-1b, IL-6, TNF-a,
IFN-c), growth factors (e.g. EGF, GMC-SF, TGF-b), and
chemokines (e.g. CCL2, CXCL1, CXCL8, CXCL9, CXCL10,
CXCL11) may be involved in the development of pulmonary
inflammation, emphysema, and fibrosis around small airways in
COPD [6]. Furthermore, Th17 cells can also activate neutro-
phils, and are thought to contribute to the development of COPD
[4,6].
The proinflammatory cytokines IL-1, IL-18, and IL-33 belongs
to the IL-1 family [7]. IL-18 is well known to play an important
role in Th1 polarization, and can also act as a co-factor for Th2
cell development and IgE production [8–11]. Recently, IL-18 was
reported to take part in the differentiation of Th17 cells by
amplifying IL-17 production by polarized Th17 cells in synergy
with IL-23 [12]. IL-18 plays important roles in the pathogenesis of
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arthritis (RA), adult-onset Still’s disease, Sjo ¨gren’s syndrome, and
inflammatory bowel diseases including Crohn’s disease [see review
[8]]. IL-18 is also involved in the development of inflammatory
lung diseases including pulmonary inflammation, asthma, lung
injury and idiopathic pulmonary fibrosis (IPF) [14,15] [16].
Previously, we showed that constitutive overproduction of mature
IL-18 protein in the lungs of transgenic mice resulted in severe
emphysema accompanied by pulmonary inflammation [17]. A
significant negative correlation between the serum IL-18 level and
%FEV1 has also been reported in COPD [18]. Taken together,
these results provide strong support for the involvement of IL-18 in
the pathogenesis of COPD.
Mammals are not able to synthesize or metabolize chitin.
However a number of chitinolytic chitinase-like proteins including
acidic mammalian chitinase (AMCase), chitinase 3-like 1 (Chi3l1),
and chitin-binding protein, belonging to the 18 glycosyl-hydrolase
family, have been discovered in mice [19]. Chi3l1, which is also
known as breast regression protein (BRP)-39 and cartilage gp39,
and its human homolog YKL-40 (also known as human cartilage
gp39), have been regarded as prototype chitinase-like proteins in
mammals [19]. Recent studies have demonstrated increased levels
of YKL-40 protein and/or mRNA in serum or tissues of patients
with inflammatory diseases, including RA, osteoarthritis (OA),
sarcoidosis, and several types of malignancy [see review [20]].
YKL-40 is thought to be a useful prognostic or diagnostic
biomarker for coronary artery disease and cancer [21][22]. In
addition, YKL-40 and chitinase-like protein may be involved in
the pathogenesis of asthma in humans, as well as in a mouse
asthma model [23–25]. Recently, elevated levels of YKL-40 in
serum, BALF, and/or lung tissues of COPD patients have been
reported [26][27]. In the present study, we determined mRNA
expression profiles in the lungs of our murine model of COPD, the
IL-18-transgenic mouse [17], using microarray analysis. We found
that the levels of mRNAs for chitinase-like proteins Chi3l1,
Chi3l3, and AMCase were significantly increased in the lungs of
IL-18-transgenic mice as compared with control wild-type mice.
Moreover, the protein levels of YKL-40 were significantly higher
in serum samples from smokers and COPD patients than in those
from non-smokers. In COPD patients, there was a significant
negative correlation between the serum level of YKL-40 and
%FEV1. In contrast, there was a significant positive correlation
between the serum level of YKL-40 and the low-attenuation
area percentage (LAA%) in COPD patients. In the light of
the findings presented here, we discuss the potential roles of YKL-
40 and chitinase-like protein in pulmonary inflammation and
emphysema.
Methods
Lung-specific IL-18-transgenic (Tg) mice
We used female C57BL/6N (B6) background SPC-IL-18 Tg
mice in which the mature mouse IL-18 was overproduced in the
lungs under the control of the human surfactant protein (SP) C
promoter [17]. We established B6 IL-13 (2/2) SPC-IL-18 Tg
mice by backcrossing SPC-IL-18 Tg mouse line A with B6 IL-13
(2/2) mice, as reported previously [28]. Age-matched female B6
wild-type (WT) mice, purchased from Charles River Japan
(Yokohama, Japan), were used as controls. All procedures were
approved by the Committee on the Ethics of Animal Experiments,
Kurume University (Approval No. H22-079-084). Animal care
was provided in accordance with the procedures outlined in the
‘‘Principle of laboratory animal care’’ (National Institutes of
Health Publication No.86-23, revised 1985).
RNA isolation
Lung tissues were obtained from both Tg and control WT B6
mice, and frozen immediately in liquid nitrogen. Total RNA was
isolated by homogenization of the lung tissues in Trizol reagent
(Invitrogen, Tokyo, Japan) using a Polytron PT2100 (Kinematica
AG, Littau, Switzerland), as reported previously [14].
DNA microarray analysis
A Whole Mouse Genome Oligo Microarray Kit H (catalog
no. G4121A, Agilent Technologies, Tokyo, Japan) was used for
the DNA microarray analysis. We individually hybridized 500 ng
of total RNA isolated from each Tg and control mouse. RNAs
isolated from WT and Tg mice were labeled with Cy5 and Cy3,
respectively, and the Cy3/Cy5 ratio was used as an absolute
indicator of the fold-change of expression in the SPC-IL-18 Tg
mouse relative to the WT control. GeneSpring softwareH (Agilent
Technologies) was used for analysis.
Quantitative real-time reverse transcriptase (RT) PCR
TaqMan RT-PCR was performed using a LightCycler 480 and
Universal Probe Library Probes (Roche Diagnostics, Tokyo,
Japan), as reported previously [13]. Briefly, first-strand cDNAs
were synthesized using oligo (dT)12–18 primers from total RNA
(4 mg) using a First-Strand cDNA Synthesis kit (Invitrogen).
TaqMan PCR reactions were carried out using premade kits
from Roche Diagnostics, and 5 ml of 5-fold-diluted cDNA was
used in each 20-ml reaction volume. The mixture solution was
denatured for 10 min at 95uC and then subjected to 45 two-step
amplification cycles, each comprising an annealing/extension step
at 60uC for 25 s, followed by denaturation at 95uC for 10 s. The
primer sequences were:
Mouse IL-18 sense primer: 59- CATGTACAAAGAC-
AGTGAAGTAAGAGG –39;
Mouse IL-18 antisense primer: 59-TTTCAGGTGG-
ATCCATTTCC-39;
Mouse Chi3l1 sense primer: 59-AGGCTTTGCGGT-
CCTGAT-39;
Mouse Chi3l1 antisense primer: 59-CCAGCTGGTG-
AAGTAGCAGA-39;
Mouse Chi3l3 sense primer: 59-GAACACTGAGC-
TAAAAACTCTCCTG -39;
Mouse Chi3l3 antisense primer: 59-GAGACCATGG-
CACTGAACG-39;
Mouse GAPDH sense primer: 59-TGTCCGTCGTG-
GATCTGAC-39;
Mouse GAPDH antisense primer: 59-CCTGCTTCAC-
CACCTTCTTG -39;
Relative expression levels were determined using the delta delta
Ct method. Amplification of the gene for mGAPDH was
performed on all samples tested to control for variations in RNA
content, and all transcript values were normalized with reference
to the GAPDH mRNA level.
ELISA assays
The whole lung tissues were homogenized in 2 ml of lysis buffer
(1% Triton X-100, 10 mM Tris-HCl, 5 mM EDTA, pH 7.6)
containing a protease inhibitor cocktail (Complete
TM Mini,
Boehringer Mannheim GmbH, Mannheim, Germany) and
centrifuged at 20,0006 g for 15 min. The supernatant was then
collected and stored at 280uC until ELISA assay, as reported
previously [15]. Sandwich ELISA kits were used for mouse
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YKL-40 (Quidel Corporation, San Diego, CA). The limit of kit
sensitivity was 16.0 pg/mL and 20 ng/mL, respectively.
Human subjects
Serum samples were obtained from 30 non-smokers, 28
smokers, and 45 COPD patients. Forty-five COPD patients
diagnosed with COPD were monitored at Kurume University
Hospital (Kurume Japan), Fukuoka University Hospital (Fukuoka,
Japan), Chikugogawa Onsen Hospital (Ukiha, Japan), Kirigaoka
Tsuda Hospital (Kitakyushu, Japan), Shigemoto Hospital (Shimo-
noseki, Japan), Keisinkai Hospital (Tosu, Japan), Tokunaga-Naika
Clinic (Fukuoka, Japan), the Social Insurance Futase Hospital
(Iizuka, Japan), and Arao Central Hospital (Arao, Japan). Table 1
give details (number, age, sex, GOLD Stage, smoking history,
body mass index [BMI], pulmonary function, and treatment) of all
subjects. All patients with COPD were diagnosed on the basis of
clinical history, physical examination, chest X-ray, chest computed
tomography, and pulmonary function tests in accordance with the
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
clinical criteria for the diagnosis and severity of COPD [29].
Written informed consent was obtained from each subject. Sample
collection and all procedures were approved by the ethics
committee of Kurume University (Approval No. 08067).
Pulmonary function tests
Predicted normal values for Japanese individuals were used to
calculate the predicted FEV1, which met the Japanese Pulmonary
Function Standard stipulated by the Japanese Respiratory Society
[30,31].
Assessment of HRCT
HRCT was performed at suspended full inspiration, 1-mm slice
thickness, a 10-mm gap, and the smallest field of view that include
both lungs using a CT scanner (Light Speed Ultra, GE
Healthcare, Milwaukee, WI, USA). The three images were
obtained at three anatomical levels: (a) near the superior margin
of the aortic arch (level of the upper lung zone); (b) at the level of
the tracheal carina (level of the middle lung zone); and (c) at the
level of the orifice of the inferior pulmonary veins (level of the
lower lung zone). The lungs were divided into six zones (upper,
middle, and lower on both sides), and each zone was evaluated
separately. Emphysema was assessed by using a density mask with
a cutoff of 2950 Hounsfield units to calculate LAA% as previously
reported [32] [33].
Statistical analysis
Data were presented as the mean 6 standard error of the mean
(SEM). Differences between two groups were analyzed by the
Wilcoxon rank-sum test. Statistical analysis was performed with
the JMP 7.0.1 software package (SAS Institute Japan, Tokyo,
Japan). Differences were considered significant at P,0.05.
Results
K-means clustering analysis of 608 genes
Lung tissues were obtained, and total RNA extracted from
SPC-IL-18 Tg and control Tg negative littermate mice at 5, 9, and
13 weeks of age (n=3 per group). It was found that the mRNA
levels of 608 genes were altered ,0.5-fold or .2-fold at 5, 9, and/
or 13 weeks of age in the lungs of Tg mice relative to those in
control Tg negative mice. We classified these 608 genes into 4
groups using K-means clustering analysis. Group 1 included 140
genes whose expression levels were constitutively enhanced in the
lungs of Tg mice at 5, 9, and 13 weeks. Group 2 included 215
genes whose expression levels were elevated gradually with aging.
Group 3 included 171 genes whose expression levels were
decreased gradually with aging. Group 4 included 82 genes whose
expression levels were decreased at 9 weeks of age. In group 1
(Table S1), we demonstrate that several genes including those for
IL-18 (transgene), chloride channel calcium activated 3 (Clca3),
and the chitinase-related genes chitinase 3-like 3 (Chi3l3), Chi3-
like 1 (Chi3l1) and acidic mammalian chitinase (AMCase), were
strongly upregulated in the lungs of Tg mice from 5 to 13 weeks of
age. Immunoglobulin (Ig), Ig receptor, small inducible cytokines,
complement genes, major histocompatibility (MHC) class I and
class II antigens, amyloid, chemokines, and apoptosis-related
genes were also constitutively increased at 5 to 13 weeks of age. In
group 2 (Table S2), Igs, cholesterol 25-hydroxylase (Ch25h), small
Table 1. Clinical characteristics of COPD patients, smokers,
and non-smokers examined in this study.
Non-smoker Smoker COPD
No. of patients 30 28 45
Age (years) 64.662.6 61.862.5 67.961.3
Sex
Male 13 23 38
Female 17 5 7
GOLD
Stage I 0 0 11
Stage II 0 0 15
Stage III 0 0 11
Stage IV 0 0 8
Smoking history
Current 0 28 23
Ex-smoker
(Years since quitting smoking)
00 2 2
(6.7561.2)
Pack-years 0 35.063.7
* 56.563.7
*{#
BMI 20.160.7 20.960.8 21.260.5
%FVC 93.9764.8 97.064.4 84.964.1
%FEV1 115.864.4 102.963.5 58.564.0
*{
FEV1% (FEV1/FVC) 83.962.0 78.861.5 48.162.2
*{
Treatment
Systemic steroids 0 0 0
LAMA 0 0 15/39 (38.5%)
ICS 0 0 12/39 (30.8%)
LABA 0 0 18/39 (46.2%)
Other bronchodilators
a 0 0 10/39 (25.6%)
No drug treatment 30/30 (100%) 28/28 (100%) 16/39 (41.0%)
*P,0.05 vs. non-smoker.
{P,0.05 vs. smoker.
#Smoking history in patients with stage I , II, III, and IV COPD were 51.867.7,
60.867.9, 56.265.7 and 56.367.0 pack-years, respectively.
a: Methylxanthines or Oxitropium bromide.
COPD: Chronic Obstructive Pulmonary Disease.
GOLD: Global Initiative for Chronic Obstructive Lung Disease.
BMI: body mass index.
FVC: forced vital capacity.
FEV1: forced expiratory volume in one second.
LAMA: long-acting muscarinic antagonists.
ICS: inhaled corticosteroids.
LABA: long-acting b2-agonists.
doi:10.1371/journal.pone.0024177.t001
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apoptosis-related genes including caspase showed a gradual
increase of expression with age. In group 3 (Table S3), several
genes including spermine binding protein, cytochrome P450
(CYP4B1, CYP2F2, CYP2A4, CYP2S1), antioxidant genes (e.g.
glutathione s-transferase (GST) and peroxiredoxin), G-protein-
coupled receptors (GPCRs, olfactory receptor-like), aquaporin and
myosin showed a gradual decrease of expression with age. Among
the 82 genes of group 4, those such as GPCR (olfactory receptor-
like) and P450 (26A2) showed a transient decrease at 9 weeks of
age (Table S4).
Increased levels of Chi3l1 and Chi3l3 expression in the
lungs of COPD model mice
Three chitinase-related genes, Chi3l1, Chi3l3 and AMCase,
were strongly upregulated in the lungs of SPC-IL-18 Tg mice from
5 to 13 weeks (Table S1). To validate these results, TaqMan RT-
PCR was used to assess RNA samples isolated from the lungs of 5-
week-old female Tg and control WT B6 mice (n=4 per each
group). Quantitative RT-PCR analysis demonstrated that the
expression levels of Chi3l1, Chi3l3, and IL-18 mRNAs in Tg mice
were 3.7-, 10.6-, and 99.0-fold higher than in control WT mice,
respectively. There were significant (p,0.01) differences in the
expression levels of Chi3l1, Chi3l3 and IL-18 (transgene) in the
lungs when compared to those in Tg and WT mice (Fig. 1A). Gene
array analysis showed that the expressions levels of IL-18 mRNA
in Tg mice were approximately 5- to 7-fold higher than in WT
mice at 5, 9, and 13 weeks of age (average increase, 5.93-fold; see
Table S1), similar to data that we have previously reported [17].
We then examined Chi3l1 protein levels in the lungs and sera of
Tg and WT mice. Lung tissues were obtained from 7-, 16- and 24-
week-old SPC-IL-18 Tg and WT control mice (n=4 per each
group) and ELISA analysis showed that the level of Chi3l1 protein
in the lungs of WT mice did not alter significantly during aging,
whereas there was a significant increase of Chi3l1 protein in the
lungs of SPC-IL-18 Tg mice. Moreover, the level of Chi3l1 protein
increased significantly (P,0.05, 7 weeks vs. 24 weeks) with age in
the lungs of SPC-IL-18 Tg mice. The serum levels of Chi3l1 level
were significantly increased in IL-18 Tg mice when compared with
control wild type mice at 16 and 24 weeks (Fig. 1B). We also
examined the levels of IL-18 protein in the lung and sera of IL-18
Tg mice. The ELISA analysis showed the levels of IL-18 in the
lungs and sera were significantly increased in IL-18 Tg mice when
compared with control wild type mice. The level of IL-18 protein
increased significantly with age in the lungs and sera of IL-18 Tg
mice (Fig. 1B), as we previously reported [17].
IL-13 gene deletion does not reduce the level of Chi3l1
protein in the lungs of IL-18-transgenic mice
Previous studies have suggested that Chi3l3 and AMCase are
IL-13-driven chitinase-like proteins [25,34]. Therefore, we
evaluated whether IL-13 gene deletion would reduce the level of
Chi3l1 protein in the lungs of IL-18-transgenic mice. We
established B6 IL-13 (2/2) SPC-IL-18 Tg mice by backcrossing
SPC-IL-18 Tg mouse line A with B6 IL-13 (2/2) mice. ELISA
analysis revealed that IL-13 gene deletion did not significantly
reduce the level of Chi3l1 protein in the lungs of the IL-18-
transgenic mice (Fig. 2).
Expression levels of YKL-40 in sera of non-smokers,
smokers and COPD patients
Based on our data with the transgenic mouse model, we next
asked if similar changes in the chitinase-like genes could also be
observed in patients with significant lung inflammation, i.e.
smokers and COPD patients. Data classifying the patients is
shown in Table 1. Serum levels of YKL-40 in current smokers
without COPD (331.8637.0 ng/mL, n=28) and COPD patients
(268.9632.3 ng/mL, n=45) were significantly (P,0.01) higher
than those in non-smokers (177.8622.6 ng/mL, n=30). The
serum levels of YKL-40 did not differ significantly between 28
current smokers without COPD and the 45 COPD patients.
Serum levels of YKL-40 in 23 current smokers with COPD and 22
ex-smokers with COPD were 254.5641.1 and 283.9651.0 ng/
mL, respectively. There were no significant differences in serum
YKL-40 levels between current smokers with COPD and ex-
smokers with COPD. The serum levels of YKL-40 in 23 current
smokers with COPD were not significantly higher than those in 28
current smokers without COPD, or in 30 non-smokers. Next, we
classified the 45 COPD patients according to the GOLD
classification of COPD severity . Serum YKL-40 levels in GOLD
stages I (n=11), II (n=15), III (n=11), and IV (n=8) were
181.6638.2, 199.4639.8, 376.2659.6, and 371.66120.6 ng/mL,
respectively. Interestingly, the serum levels of YKL-40 in GOLD
stages III and IV, but not stages I, or II, were significantly
(P,0.01) higher than those in non-smokers. The serum levels of
YKL-40 in GOLD stage III were significantly (P,0.01) higher
than those in stages I or II. It is of note that the serum levels of
YKL-40 in some smokers were over 600 ng/mL (Fig. 3). Next, the
correlation between serum levels of YKL-40 and pulmonary
function was analyzed in nonsmokers, smokers and COPD
patients. In COPD patients, there was a significant (P,0.05)
negative correlation between serum level of YKL-40 and predicted
FEV1 (%FEV1) (r=0.338) (Fig. 4A) but not between serum YKL-
40 and %FVC (Fig. 4B). In contrast, no significant correlations
between serum levels of YKL-40 and %FEV1 were observed in
nonsmokers or smokers (data not shown). Serum levels of IL-18 in
smokers (n=28, 216.5615.5 pg/mL) and COPD patients (n=40,
235.4613.2 pg/mL) were significantly (P,0.0001) higher than
those in nonsmokers (n=30, 113.7613.5 pg/mL), as we previ-
ously reported [18]. There was a significant association between
serum levels of IL-18 and YKL-40 among nonsmokers, smokers
and COPD patients (data not shown). We evaluated whether ICS
treatment influenced serum levels of YKL-40 in COPD patients.
However, we observed that ICS treatment did not significantly
affect serum levels of YKL-40 in COPD patients.
Positive correlation between serum level of YKL-40 and
LAA% in COPD patients
Sixteen COPD patients had undergone HRCT examination,
LAA% was calculated, and serum levels of YKL-40 were examined.
In COPD patients, there was a significant (P,0.0001) positive
correlation between serum level of YKL-40 and LAA% (%FEV1)
(r=0.830) (Fig. 5).
Discussion
Smoking is recognized to be the largest risk factor for COPD.
Cigarette smoke is a major source of reactive oxygen species
(ROS), exposure to which can lead to pulmonary inflammation
and emphysema [2]. In fact, treatment with antioxidants has been
shown to decrease the degree of oxidative damage in COPD
patients and COPD animal models. For example, orally
administered N-acetylcysteine (NAC) reduces the viscosity and
purulence of phlegm in COPD patients [35]. CuZn superoxide
dismutase is known to be a strong antioxidant, and Tg mice
overproducing human CuZn superoxide dismutase do not develop
pulmonary inflammation in models of pulmonary emphysema
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antioxidant thioredoxin 1 (TRX1) inhibits elastase-induced em-
physema in mice [37]. In the present study, we showed that
expression of antioxidant genes such as GST, SOD1, and SOD3
was decreased in the lungs of IL-18 Tg mice. These results suggest
that decreased antioxidant activities in the lungs may contribute to
pulmonary inflammation and emphysema in the COPD mouse
model .
Cathepsins are lysosomal cysteine proteases involved in the
pathogenesis of COPD [5,38]. Expression of cathepsin S is
induced by IFN-c in several cell types, including smooth muscle
cells. Increased levels of cathepsin L have been observed in BALF
of patients with emphysema, and alveolar macrophages from
COPD patient secrete more cysteine protease than macrophages
from smokers without disease, or those from non-smokers [5].
Overexpression of IFN-c in the lungs induces emphysema in mice
with increased expression of cathepsins B, D, H, L and S [39]. In
the present study, we found that cathepsins S, D, B, Z, L and C
were strongly expressed in the lungs of IL-18 Tg mice, and that
Figure 1. Expression of chitinase-related genes in the lungs of ling-specific IL-18 transgenic mice. (A) TaqManRT-PCRanalysisofchitinase
3-like 1 (Chi3l1), chitinase 3-like 3 (Chi3l3), and IL-18 (transgene) mRNA expression in the lungs of 5-week-old SPC-IL-18-Tg (TG) mice, in comparison with
control wild type (WT) mice (n=4, each group).
* P,0.01 vs. WT mice. (B) Lung tissues and sera were obtained from 7-, 16- and 24-week-old SPC-IL-18-Tg
and control WT mice (n=4 per group).The whole lungtissues werehomogenized in 2 ml oflysis buffer, as described in Methods.The levels ofChi3l1 and
IL-18 protein in the lungs and sera were analyzed using sandwich ELISA kits *: P,0.01 vs. WT mice. +:P ,0.05 vs. 7-week-old Tg mice.
doi:10.1371/journal.pone.0024177.g001
Figure 2. The effects of IL-13 gene deletion on the expression
of Chi3l1 in the lungs of lung specific IL-18 transgenic mice.
Lung tissues were obtained from 21- to 24-week-old B6 SPC-IL-18 Tg, B6
IL-13 (2/2) (KO) SPC-IL-18 Tg, B6 IL-13 (2/2) and control B6 WT mice
(n=4 per group). The whole lung tissues were homogenized in 2 ml of
lysis buffer, and then the levels of Chi3l1 protein in the lungs were
analyzed using sandwich ELISA kits, as described in Methods. *: P,0.05
vs. WT mice. +:P ,0.05 vs. IL-13 (2/2) mice.
doi:10.1371/journal.pone.0024177.g002
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results suggest that in Tg mice, overexpression of IL-18 may
increase the levels of cathepsins, which may in turn induce the
development of emphysematous changes in the lungs.
In the present study we found that the levels of mRNA and/or
protein for the chitinase-related genes Chi3l1, Chi3l3, and
AMCase were strongly increased in the lungs of IL-18 Tg mice,
relative to Tg negative littermate mice, suggesting that IL-18
induces the expression of chitinase-related genes in vivo. Previous
studies have demonstrated that IL-13 directly induces the
expression of Chi3l1 in vivo [34] and Chi3l1 induction by cigarette
smoke was found to be partly dependent on the IL-18 pathway. In
contrast, IL-18 induction was not significantly modulated in the
absence of the Chi3l1 gene, suggesting that Chi3l1 operates
downstream of IL-18 [27]. A previous study reported that
AMCase was greatly induced in lung-specific IL-13 transgenic
mice over-expressing mouse IL-13 proteins in the lungs. In
contrast, AMCase was not up-regulated relative to WT mice in the
IL-13 (2/2) mouse asthma model [25]. These results suggest that
Chi3l3 and AMCase are IL-13-driven chitinase-like proteins. We
have reported that IL-18 induces both Th1 and Th2 cytokines,
including IL-13 and IFN-c in vivo and in vitro (9–11). Moreover,
disruption of the IL-13 gene but not the IFN-c gene prevented
emphysema and pulmonary inflammation in SPC-IL-18 Tg mice
[17]. Therefore, we hypothesized that the expression of Chi3l1
induced by IL-18 is at least partly dependent on the IL-13
pathway in vivo. We established IL-13 (2/2) SPC-IL-18 Tg mice
by backcrossing B6 SPC-IL-18 Tg mice with B6 IL-13 (2/2)
mice. However, IL-13 gene deletion did not significantly reduce
the protein level of Chi3l1 in the lungs of IL-18 transgenic mice,
suggesting that IL-18 drives the expression of Chi3l1 indepen-
dently of the IL-13 pathway. Previous studies have demonstrated
that the proinflammatory cytokines TNF-a and IL-1b both
regulate the expression of YKL-40 in articular chondrocytes via
NF-kB signaling [40]. Various inflammatory cytokines including
IL-13, IFN-c, IL-1a, IL-1b, and IL-12 were greatly up-regulated
in the lungs of lung-specific IL-18-Tg mice [17]. Therefore it is
suggested that IL-18 regulates the expression of multiple
inflammatory cytokines, together with Chi3l1.
In this study, we found that Chi3l1 protein was induced in the
lung of SPC-IL-18 Tg mice. However, as we examined levels of
Figure 3. Serum levels of YKL-40 in smokers and a subset of
COPD patients. Serum samples were obtained from 30 non-smokers,
28 current smokers, and 45 COPD patients (GOLD stages I [n=11], II
[n=15], III [n=11], and IV [8]), and analyzed for YKL-40 protein levels
using sandwich ELISA kits. *: P,0.01 vs. nonsmokers. +:P ,0.05 vs.
GOLD stages I or II.
doi:10.1371/journal.pone.0024177.g003
Figure 4. Relationship of serum levels of YKL-40 with %FEV1
and %FVC in COPD patients. Serum YKL-40 levels and %FEV1 (A)
and %FVC (B) in COPD patients (n=45) were analyzed.
doi:10.1371/journal.pone.0024177.g004
Figure 5. Positive correlation between serum level of YKL-40
and LAA% in COPD patients. Sixteen COPD patients had undergone
high resolution computed tomography (HRCT) examination. Emphyse-
ma was assessed by using a density mask with a cutoff of 2950
Hounsfield units to calculate the low-attenuation area percentage
(LAA%). Serum levels of YKL-40 and LAA% were evaluated in COPD
patients.
doi:10.1371/journal.pone.0024177.g005
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type of cells are the major source of Chi3l1 in these mice.
Unfortunately we have not been able to identify the cellular source
as the commercial anti-goat mouse Chi3l1 polyclonal antibody
was not suitable for immunohistochemistry. Next, we examined
whether IL-18 can induce Chi3l1 protein from lymphocytes.
Spleen cells were isolated from wild type B6 mice, and were passed
through nylon wool column. The nylon wool column-passed cells
(2610
6/mL) were stimulated with recombinant human IL-2
(100 U/mL), recombinant mouse IL-18 (100 ng/mL), or IL-2
plus IL-18. Cells were stimulated for 18 hrs, and the supernatants
were harvested. ELISA analysis showed that stimulation with IL-2
plus IL-18 induced IL-13 and IFN-c production from the cells as
we previously reported [9]. In contrast, stimulation with IL-2, IL-
18 or IL-2 plus IL-18 did not induced Chil1 production from the
spleen cells (data not shown). Our results suggest that the Chi3l1 is
induced via paracrine mechanisms. Further analysis and better
biochemical tools are needed to clarify these issues.
We believe that our mouse model is a useful system to help us
understand the changes taking place in the lungs of smokers and
those patients with COPD. Letuve el. al. analyzed the serum levels
of YKL-40 in 15 non-smokers, 20 current smokers and 30 COPD
patients (comprising 14 current smokers and 16 ex-smokers) [26].
Very recently, Matsuura conducted similar measurements in 12
non-smokers, 11 (presumably current) smokers without COPD
and 18 (presumably current) smokers with COPD [27]; both
studies indicated that the serum levels of YKL-40 in smokers with
COPD were significantly higher than those in smokers without
COPD, or in non-smokers. Matsuura also has reported that the
number of YKL-40+ cells in the lungs was significantly increased
in current smokers than seen in ex-smokers or nonsmokers, but
serum levels of YKL-40 was not increased in current smokers [27].
It is of note that two of the previous studies [26][27] evaluated the
serum levels of YKL-40 in relatively small numbers of subjects. In
the present study, we analyzed the serum levels of YKL-40 in 30
nonsmokers, 28 current smokers without COPD and 45 COPD
patients (comprising 23 current smokers and 22 ex-smokers). We
found that the serum levels of YKL-40 in current smokers without
COPD, and those in COPD patients, were significantly higher than
in non-smokers.However, the serum levels of YKL-40did not differ
significantly between current smokers with COPD and current
smokers without COPD patients, and there were no significant
differences in serum YKL-40 levels between current smokers with
COPD and ex-smokers with COPD. Similar to our results, Agapov
showed that the serum levels of YKL-40 in current- and ex-smokers
with COPD were not significantly higher than those in current
smokers without COPD [41]. Overall, the results suggest that
cigarette smoke may increase the serum level of YKL-40.
In this study, we found there was a significant negative
correlation between serum levels of YKL-40 and %FEV1 in
COPD patients. Previous studies reported that the decline of
%FEV1 was correlated with emphysematous changes in COPD
patients [32][33]. These results suggest that serum levels of YKL-
40 are associated with emphysematous changes in COPD patients.
Therefore, we evaluated the relationship of serum levels of YKL-
40 with LAA% in COPD patients. We found a very close
association between serum levels of YKL-40 and LAA% in COPD
patients. However, there was no significant association between
serum levels of IL-18 and LAA% in COPD patients (data not
shown). These results suggest that YKL-40 may be involved in the
development of emphysematous changes in COPD patients.
In conclusion, our results demonstrate that chitinase-related
genes (including Chi3l1, Chi3l3, and AMCase) and IL-18 may
play an important role in the establishment of pulmonary
inflammation and emphysematous change in COPD. The lung-
specific IL-18 Tg mouse is a new model that closely resembles
human COPD, and thus may be useful for screening drugs that
could inhibit or slow the progression of this disease.
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